#United States #Class Action #New Orleans #Kahn Swick #ADMA Biologics

Overview of the Lawsuit

ADMA Biologics, Inc., a company listed on Nasdaq, is currently facing a class action lawsuit concerning allegations of misleading information that affected its investors negatively. According to Kahn Swick & Foti, LLC, which is representing the interests of these investors, the lawsuit encompasses claims regarding significant material omissions made by the company during their initial offering documents.

Background Information

The class action involves investors who purchased ADMA’s securities from August 9, 2024, to March 25, 2026. The specifics of these claims highlight that ADMA and its executives failed to disclose critical information, thereby violating federal securities laws. Allegations include undisclosed related party transactions, the use of channel stuffing to project inflated revenue figures, and significant deficiencies in internal controls. Such misrepresentations resulted in damages to investors once the truth surfaced.

Details of the Allegations

The lawsuit, identified as Mazzarino v. ADMA Biologics, Inc., et al., asserts multiple violations on part of the company:

1. Undisclosed Transactions: It's claimed that ADMA engaged in related party transactions that were not adequately reported to their investors.
2. Channel Stuffing Practices: Evidence suggests that ADMA may have engaged in manipulative practices to inflate their revenue outlook, misleading potential and existing investors.
3. Inadequate Internal Controls: The lawsuit highlights a serious lack of proper oversight and internal control measures within the company, calling into question the reliability of their financial statements.

The accumulation of these issues led to statements made by the Defendants about the company being materially false and misleading.

Next Steps for Investors

For individuals who invested in ADMA Biologics during the specified period and incurred losses, the applying deadline to request appointment as a lead plaintiff is August 10, 2026. Although serving as a lead plaintiff may strengthen your position, those who have suffered losses need not take on this role to partake in any potential recovery resulting from the lawsuit.

How to Get Involved

Investors who are interested in participating in this class action are encouraged to reach out to Lewis Kahn, Managing Partner at Kahn Swick & Foti, LLC, for further information. They can contact him toll-free at 1-877-515-1850 or via email at email protected] Completing the process is straightforward, and interested parties can find more information at [Kahn Swick & Foti’s website.

Conclusion

As the class action deadline looms, it becomes increasingly crucial for affected investors to remain informed and proactive regarding their legal rights and options. This case underscores the importance of transparency and accuracy in corporate communications, and the potential impact of negligence or malfesance on investors. Keeping abreast of developments in this case will be critical for those connected to ADMA Biologics, Inc.

For more insights and updates on this litigation, stay tuned to Kahn Swick & Foti’s communications, as they continue to navigate the complexities of securities litigation in pursuit of justice for investors.